Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Ultragenyx Pharmeutical News

    45,48 $ +4,10% +1,79 $
    In : 42,486 € | 19:44:00 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1XCY0
    ISIN: US90400D1081
    US-Symbol: RARE
    Typ: Aktie

    Ultragenyx Pharmeutical News

    04.01.24 - GlobeNewswire
    Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
    NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence ...
    18.12.23 - GlobeNewswire
    Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
    For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-​in-class medicine to treat an ultrarare, inherited form of high cholesterol
    18.09.23 - Wikifolio
    Die heißesten Aktien der letzten Woche
    Hier erfährst du, welche Aktien letzte Woche besonders oft ge- oder verkauft wurden und welche Motive dafür entscheidend waren.
    01.09.23 - GlobeNewswire
    Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
    Evkeeza® ist das erste von der U.S. Food and Drug Administration (FDA) und der Europäischen Kommission (EC) zugelassene Medikament einer neuen Klasse zur Behandlung ...
    29.08.23 - PR Newswire
    TSX Venture Exchange Stock Maintenance Bulletins
    TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire
    09.09.21 - GlobeNewswire
    MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
    NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel ...
    13.07.21 - GlobeNewswire
    MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
    MADRID, Spain, July 13, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel ...
    31.03.20 - PR Newswire
    REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
    REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder - REGENXBIO grants Ultragenyx ...
    15.01.20 - PR Newswire
    Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart?
    Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart? PR Newswire
    17.05.18 - PR Newswire
    Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophos
    Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in ...
    23.02.18 - PR Newswire
    Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung in Europa zur Behandlung der X-chromosomalen Hypophosphatämie erhält
    Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung in Europa zur Behandlung der X-​chromosomalen Hypophosphatämie erhält PR ...
    23.02.18 - PR Newswire
    Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
    Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children ...
    23.02.18 - PR Newswire
    Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
    Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children ...
    15.11.17 - PR Newswire
    Thinking about buying Acorda Therapeutics, JA Solar, Ultragenyx Pharmaceuticals, Square Inc. or Target?
    Thinking about buying Acorda Therapeutics, JA Solar, Ultragenyx Pharmaceuticals, Square Inc. or Target? PR Newswire
    13.10.17 - PR Newswire
    WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
    WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders PR Newswire
    03.03.17 - PR Newswire
    PriceWatch Alert: High return covered-call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY
    PriceWatch Alert: High return covered-​call trades for Cliffs Natural Resources, JD.com, Realty Income, Ultragenyx Pharmaceuticals and YY PR Newswire
    28.10.16 - PR Newswire
    Covered Call reports for CenturyLink, Francesca's Holdings Company, Myriad Genetics, Stamps.Com Inc. and Ultragenyx Pharmaceuticals include trade ideas that offer returns of 19% or more!
    Covered Call reports for CenturyLink, Francesca's Holdings Company, Myriad Genetics, Stamps.Com Inc. and Ultragenyx Pharmaceuticals include trade ideas that offer returns of ...

    Newssuche

    Videos

    newspaper
    09:10 Uhr -3,35%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »